Michael Palfreyman

Michael Gavin Palfreyman was the founder of Amorsa Therapeutics, Inc. (2013) and served as Chief Scientific Officer.
Dr. Palfreyman is also the founder of Scriptgen Pharmaceuticals, Inc. Dr. Palfreyman is currently a Director at Amakem NV since 2011 and Vice President-Development at Brenig Therapeutics, Inc. Former positions include Chief Operating Officer & Director at Adelia Therapeutics, Inc., Chief Scientific Officer at Marc Pharmaceuticals, Inc., VP-Program Management & Product Development at FORUM Pharmaceuticals, Inc., Principal at Psychiatric Genomics, Inc., Principal at Torrey Pines Investment, Inc., and Chief Research & Development Officer at Cybin, Inc. Education includes a doctorate (1970), an undergraduate degree (1967), and a graduate degree (1971) from The University of Nottingham.